Hamood Rehman

Hamood Rehman

Auto-generated profile, based on publicly available information

Hamood Rehman

Department of Animal Sciences, College of Agriculture, Purdue University, West Lafayette, IN, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2025 in Journal of Applied Physiology
Verified
Journal Article
Closed access
MBMichael David Belbis
Michael David Belbis
BRBohyun Ro
Bohyun Ro
LSLuke E. Schepers
Luke E. Schepers
KKKun Ho Kim
Kun Ho Kim
ZYZhen Yap
Zhen Yap
DHDaniel M. Hirai
Daniel M. Hirai
This is the first evaluation of the effects of heat therapy (HT) in heart failure with preserved ejection fraction (HFpEF). HT elicited multiple central and peripheral adaptations that impacted positively exercise tolerance in a preclinical model of HFpEF. HT adaptations included improvements in cardiac function, body composition, and skeletal muscle oxygenation (mediated partially via enhanced nitric oxide bioavailability). These novel findings indicate that HT may hold important clinical significance for the treatment of HFpEF.

6 October 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
HRHamood Rehman
Hamood Rehman
XLXinyue Lu
Xinyue Lu
SNSavannah M Nasrallah
Savannah M Nasrallah
BSBinayok Sharma
Binayok Sharma
SLSophie Lies
Sophie Lies
JMJames F Markworth
James F Markworth
Duchenne muscular dystrophy (DMD) is an X-linked disorder mainly affecting young boys characterized by repeated cycles of myofiber injury/regeneration and chronic muscle inflammation. Although glucocorticoids can slow disease progression, their potential long-term adverse effects highlight the need for new steroid-sparing therapies for DMD. Annexin A1 (ANXA1) is a glucocorticoid-induced pro-resolving protein that signals primarily through formyl peptide receptor 2 (FPR2). We investigated whether the ANXA1 mimetic peptide Ac2-26 could reduce inflammation, stimulate tissue regeneration, and improve skeletal muscle function in muscular dystrophy. 3-week-old dystrophin-deficient male mdx mice were randomized to receive daily intraperitoneal injections of vehicle control, deflazacort (1 mg/kg/day), or Ac2-26 (1 mg/kg/day) for a duration of 5-weeks. Body composition, skeletal muscle mass, contractile function, and tissue histopathology/immune-cell infiltration were assessed at 8-weeks of age. Direct effects on myogenesis were also examined in vitro using primary D2- mdx myoblasts. ANXA1 was expressed predominantly by myeloid cells rather than resident dystrophic muscle cells. Both deflazacort and Ac2-26 markedly reduced intramuscular inflammation and increased myofiber size. However, Ac2-26 produced broader anabolic and functional benefits, increasing body-weight gain, lean body mass, hindlimb muscle weights, and absolute contractile force. Ac2-26 treatment also directly promoted myogenesis of dystrophic myoblasts in vitro , while pharmacological FPR2 blockade impaired myotube development. Overall, Ac2-26 mimicked the anti-inflammatory effects of deflazacort while providing superior benefits for body weight and composition, skeletal muscle growth, myofiber regeneration, and absolute muscle strength. These findings support therapeutic targeting of the ANXA1–FPR2 axis as a potential safe and effective steroid-sparing immunomodulatory strategy for DMD.

10 June 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
XLXinyue Lu
Xinyue Lu
GFGabriela A. Ferraz
Gabriela A. Ferraz
SSShivani Sivakumar
Shivani Sivakumar
HTHanan Tlais
Hanan Tlais
HRHamood Rehman
Hamood Rehman
JMJames F Markworth
James F Markworth
Aging is associated with a gradual and progressive decline in skeletal muscle mass and strength known as sarcopenia, which has been attributed to chronic low-grade inflammation. Dietary long-chain polyunsaturated fatty acids (LC-PUFAs), including omega-6 arachidonic acid (ARA) and omega-3 docosahexaenoic acid (DHA), are precursors to bioactive lipid mediators that regulate the initiation, propagation, and active resolution of inflammation. While traditionally considered a pro-inflammatory and catabolic factor, the ARA-derived eicosanoid prostaglandin E 2 has recently emerged as a potential anti-sarcopenic molecule. DHA-derived specialized pro-resolving mediators may also act as immunomodulatory pro-regenerative molecules in muscle inflammaging. In the current study, we tested the effects of long-term dietary supplementation with either ARA or DHA on muscle health in aging mice. Twenty-two-month-old C57BL/6N mice were fed a control AIN-93M diet, or an AIN-93M diet supplemented with either ARA (0.48% w/w) or DHA (0.48% w/w) for 12 weeks. Both dietary interventions reduced total body weight, but only ARA reduced absolute fat mass and increased the percentage of lean mass. Despite these changes in body composition, ARA supplementation reduced absolute muscle strength and myofiber size. This functional decline was associated with increased neuromuscular junction fragmentation, elevated expression of pro-inflammatory cytokines/protein degradation markers, and suppressed ribosome biogenesis. In contrast, DHA uniquely reduced chronic inflammation of aged muscle and returned c-Myc expression to young levels but did not affect muscle mass or strength. These data demonstrate that long-term dietary intake of ARA and DHA have overall divergent effects on the structure and function of aging muscle.